Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prophylactic Treatment With Atorvastatin for Chronic Migraine (ChronicStatinMig)
Sponsor: St. Olavs Hospital
Summary
The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 2) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.
Official title: ChronicStatinMig. A Multicentre, Triple Blind, Placebo Controlled, Parallel Group Study of Atorvastatin in Chronic Migraine
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2024-05-01
Completion Date
2029-02-28
Last Updated
2025-07-01
Healthy Volunteers
Yes
Conditions
Interventions
Atorvastatin 40mg
Each tablet will be taken once daily for 84 days.
Placebo
Each tablet will be taken once daily for 84 days.
Locations (6)
Haukeland University Hospital
Bergen, Norway
University Hospital, Akershus
Lørenskog, Norway
Oslo University Hospital, Rikshospitalet
Oslo, Norway
Oslo University Hospital, Ullevål
Oslo, Norway
University Hospital Northern Norway
Tromsø, Norway
St. Olavs hospital
Trondheim, Norway